IXICO plc Additional Alzheimer's disease contracts (9975D)
03 November 2020 - 6:00PM
UK Regulatory
TIDMIXI
RNS Number : 9975D
IXICO plc
03 November 2020
IXICO plc
("IXICO" or the "Company")
Additional Alzheimer's disease contracts with new and existing
large pharma clients
IXICO plc (AIM: IXI), the data analytics company delivering
insights in neuroscience, announces that it has secured new
contracts in Alzheimer's disease (AD) clinical trials.
The new contracts include a Phase I study in Alzheimer's disease
with a new biotechnology customer, an expansion contract for a
Phase II trial with an existing biotechnology company and the
initiation of an open-label extension phase III trial with an
existing large pharmaceutical company.
The contracts build on the strength IXICO has in AD clinical
trials and are in addition to the partnership with the Global
Alzheimer's Platform which the Company announced on World
Alzheimer's Day, 21 September 2020.
These contracts were included in management's expectations of
performance for the coming year and contribute to the Company's
strong order book. These contracts relate to trials at different
stages of drug development and are with several different
customers, strengthening diversification in the Company's order
book.
Lammert Albers, Chief Commercial Officer of IXICO, commented:
"Today there are 50 million people worldwide that suffer with
Alzheimer's and other forms of dementias. There are currently no
means to prevent or delay onset, slow progression or meaningfully
improve symptoms of Alzheimer's disease. With more than 120 unique
investigational drugs in clinical trials, IXICO is proud to support
some of these potential treatments that one day may be in the hands
of Alzheimer's patients worldwide. "
For further information please contact:
IXICO plc +44 (0)20 3763 7498
Giulio Cerroni, Chief Executive Officer
Grant Nash, Chief Financial Officer
Cenkos Securities PLC (Nominated adviser
and sole broker) +44 (0)20 7397 8900
Giles Balleny / Max Gould (Corporate
Finance)
Michael F Johnson / Russell Kerr
(Sales)
Walbrook PR Ltd +44 (0)20 7933 8780
Paul McManus / Lianne Cawthorne IXICO@walbrookpr.com
/
Alice Woodings
About IXICO
IXICO is dedicated to delivering insights in neuroscience. Our
purpose is to advance medicine and human health by turning data
into clinically meaningful information, providing valuable new
insights in neuroscience and our goal is to be a leading proponent
of artificial intelligence in medical image analysis. We will
achieve this by developing and deploying breakthrough data
analytics, at scale, through our remote access technology platform,
to improve the return on investment in drug development and reduce
risk and uncertainty in clinical trials for our pharmaceutical
clients.
More information is available on www.IXICO.com and follow us on Twitter @IxicOplc
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RESEAKFAEEXEFFA
(END) Dow Jones Newswires
November 03, 2020 02:00 ET (07:00 GMT)
Ixico (LSE:IXI)
Historical Stock Chart
From Apr 2024 to May 2024
Ixico (LSE:IXI)
Historical Stock Chart
From May 2023 to May 2024